Blog
RSS FeedPosted by Michael Wonder on 01 Oct 2023
FDA approves Biogen’s Tofidence (tocilizumab-bavi), a biosimilar referencing Actemra
29 September 2023 - Tofidence (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the US. ...
Posted by Michael Wonder on 25 Sep 2023
FDA issues complete response letter for Udencya Onbody biologics license application solely due to an on-going review of inspection findings at a third-party filler
25 September 2023 - No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or ...
Posted by Michael Wonder on 21 Sep 2023
Alvotech provides US regulatory update on AVT02, a high concentration interchangeable biosimilar candidate to Humira (adalimumab)
20 September 2023 - Alvotech announced today that the US FDA has accepted Alvotech’s resubmitted biologics license application for AVT02, a ...
Posted by Michael Wonder on 30 Aug 2023
Outlook Therapeutics provides regulatory update on FDA review of ONS-5010 / Lytenava (bevacizumab-vikg) for the treatment of wet AMD
30 August 2023 - FDA issues complete response letter for ONS-5010 biologics license application based on CMC and need for further ...
Posted by Michael Wonder on 24 Aug 2023
FDA approves first biosimilar to treat multiple sclerosis
24 August 2023 - The US FDA today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment ...
Posted by Michael Wonder on 13 Jul 2023
Dr. Reddy’s proposed rituximab biosimilar application accepted for review by US FDA, EMA and MHRA
12 July 2023 - Following dossier submission in April 2023, the regulatory agencies have now accepted the dossier for review. ...
Posted by Michael Wonder on 11 Jul 2023
Express Scripts adds three biosimilars to largest formulary to promote competition and advance affordability, choices for patients
11 July 2023 - Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars ...
Posted by Michael Wonder on 10 Jul 2023
Idacio (adalimumab-aacf) now available in the United States
3 July 2023 - CMS grants Fresenius Kabi permanent, product-specific Q Code for Idacio (adalimumab-aacf). ...
Posted by Michael Wonder on 09 Jul 2023
After five years of successful experience internationally, Biocon Biologics’ Hulio biosimilar to Humira, now available in the United States
3 July 2023 - Biocon Biologics today announced that Hulio (adalimumab-fkjp) injection, a biosimilar to Humira (adalimumab), is now available ...
Posted by Michael Wonder on 03 Jul 2023
Organon & Samsung Bioepis announce US launch of Humira biosimilar Hadlima (adalimumab-bwwd) in multiple presentations consistent with originator
1 July 2023 - Individualised patient support program “Hadlima For You” available including co-pay support. ...
Posted by Michael Wonder on 03 Jul 2023
Cyltezo, first and only FDA approved interchangeable biosimilar to Humira, now commercially available in the US
1 July 2023 - Cyltezo is the only adalimumab biosimilar with Phase 3 comparative clinical studies in rheumatoid arthritis, plaque ...
Posted by Michael Wonder on 03 Jul 2023
Celltrion USA launches Yuflyma (adalimumab-aaty), a Humira (adalimumab) biosimilar, in the US
3 July 2023 - Celltrion USA today announced the launch of Yuflyma (adalimumab-aaty), a high concentration (100 mg/mL) and citrate-free formulation ...
Posted by Michael Wonder on 03 Jul 2023
Celltrion applies for approval in US for eye treatment biosimilar
30 June 2023 - The biopharmaceutical company now covers ophthalmology as well as auto-immune disease and cancer medicine. ...
Posted by Michael Wonder on 01 Jul 2023
Sandoz to launch Hyrimoz (adalimumab-adaz) high concentration formulation, marking Sandoz entrance into US immunology space
1 July 2023 - Hyrimoz (adalimumab-adaz) high concentration formulation biosimilar offers US patients reduced injection volume in citrate free formulation. ...
Posted by Michael Wonder on 30 Jun 2023
Formycon announces submission of the biologics license application for FYB203, an aflibercept biosimilar candidate to the US FDA
29 June 2023 - Formycon and its license partner Klinge Biopharma announce that the biologics license application for FYB203, a ...